Search

Alcloxa

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]

Bromotheophylline

[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.

Atazanavir

and other fatty substances in the blood). … Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.

Abiraterone

Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … [L40968, L40193, L47740, L47745] and when used in combination with niraparib, BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).

Phenylbutyric acid

Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. … It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.

Triclocarban

It is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. … In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal

Dabigatran etexilate

[A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022] … [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated.

Daprodustat

[A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin … [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia.

Deferasirox

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.